(Total Views: 114)
Posted On: 10/26/2022 2:55:52 PM
Post# of 35809

$AZN News Article - Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer https://marketwirenews.com/news-releases/cami...46784.html


My Twitter: WhyteStocks